These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
424 related articles for article (PubMed ID: 20705357)
1. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. Salazar F; Molina MA; Sanchez-Ronco M; Moran T; Ramirez JL; Sanchez JM; Stahel R; Garrido P; Cobo M; Isla D; Bertran-Alamillo J; Massuti B; Cardenal F; Manegold C; Lianes P; Trigo JM; Sanchez JJ; Taron M; Rosell R Lung Cancer; 2011 Apr; 72(1):84-91. PubMed ID: 20705357 [TBL] [Abstract][Full Text] [Related]
2. Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer. Wu JY; Yu CJ; Shih JY; Yang CH; Yang PC Lung Cancer; 2010 Mar; 67(3):348-54. PubMed ID: 19473721 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials. Zhao N; Zhang XC; Yan HH; Yang JJ; Wu YL Lung Cancer; 2014 Jul; 85(1):66-73. PubMed ID: 24780111 [TBL] [Abstract][Full Text] [Related]
4. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors. Chang MH; Ahn HK; Lee J; Jung CK; Choi YL; Park YH; Ahn JS; Park K; Ahn MJ Cancer; 2011 Jan; 117(1):143-51. PubMed ID: 20803614 [TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836 [TBL] [Abstract][Full Text] [Related]
6. A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer. Pallis AG; Voutsina A; Kentepozidis N; Giassas S; Papakotoulas P; Agelaki S; Tryfonidis K; Kotsakis A; Vamvakas L; Vardakis N; Georgoulias V Clin Lung Cancer; 2012 Mar; 13(2):129-35. PubMed ID: 22000696 [TBL] [Abstract][Full Text] [Related]
7. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Yauch RL; Januario T; Eberhard DA; Cavet G; Zhu W; Fu L; Pham TQ; Soriano R; Stinson J; Seshagiri S; Modrusan Z; Lin CY; O'Neill V; Amler LC Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8686-98. PubMed ID: 16361555 [TBL] [Abstract][Full Text] [Related]
8. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626 [TBL] [Abstract][Full Text] [Related]
9. Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Di Maio M; Gridelli C; Normanno N; Perrone F; Ciardiello F J Cell Physiol; 2005 Dec; 205(3):355-63. PubMed ID: 15895392 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation. Cho SH; Park LC; Ji JH; Park S; Hwang DW; Lee JY; Choi YL; Han JH; Sun JM; Ahn JS; Park K; Ahn MJ Cancer Chemother Pharmacol; 2012 Aug; 70(2):315-20. PubMed ID: 22760226 [TBL] [Abstract][Full Text] [Related]
11. A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer. Kawahara A; Taira T; Azuma K; Tominaga M; Hattori S; Kawahara M; Abe H; Yamaguchi T; Akiba J; Takamori S; Hayashi A; Kage M Lung Cancer; 2012 Oct; 78(1):39-44. PubMed ID: 22858448 [TBL] [Abstract][Full Text] [Related]
12. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. Taguchi F; Solomon B; Gregorc V; Roder H; Gray R; Kasahara K; Nishio M; Brahmer J; Spreafico A; Ludovini V; Massion PP; Dziadziuszko R; Schiller J; Grigorieva J; Tsypin M; Hunsucker SW; Caprioli R; Duncan MW; Hirsch FR; Bunn PA; Carbone DP J Natl Cancer Inst; 2007 Jun; 99(11):838-46. PubMed ID: 17551144 [TBL] [Abstract][Full Text] [Related]
13. Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Becker A; Crombag L; Heideman DA; Thunnissen FB; van Wijk AW; Postmus PE; Smit EF Eur J Cancer; 2011 Nov; 47(17):2603-6. PubMed ID: 21784628 [TBL] [Abstract][Full Text] [Related]
14. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038 [TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Yi HG; Kim HJ; Kim YJ; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Kim CS; Heo DS; Bang YJ Lung Cancer; 2009 Jul; 65(1):80-4. PubMed ID: 19059670 [TBL] [Abstract][Full Text] [Related]
16. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations. Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986 [TBL] [Abstract][Full Text] [Related]
17. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Kanda S; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Kubota K; Tamura T; Ohe Y Lung Cancer; 2015 Sep; 89(3):287-93. PubMed ID: 26169499 [TBL] [Abstract][Full Text] [Related]
18. Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations. Farina G; Longo F; Martelli O; Pavese I; Mancuso A; Moscetti L; Labianca R; Bertolini A; Cortesi E; Farris A; Fagnani D; Locatelli MC; Valmadre G; Ardizzoia A; Tomirotti M; Rulli E; Garassino MC; Scanni A Clin Lung Cancer; 2011 Mar; 12(2):138-41. PubMed ID: 21550561 [TBL] [Abstract][Full Text] [Related]
19. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Rosell R; Molina MA; Costa C; Simonetti S; Gimenez-Capitan A; Bertran-Alamillo J; Mayo C; Moran T; Mendez P; Cardenal F; Isla D; Provencio M; Cobo M; Insa A; Garcia-Campelo R; Reguart N; Majem M; Viteri S; Carcereny E; Porta R; Massuti B; Queralt C; de Aguirre I; Sanchez JM; Sanchez-Ronco M; Mate JL; Ariza A; Benlloch S; Sanchez JJ; Bivona TG; Sawyers CL; Taron M Clin Cancer Res; 2011 Mar; 17(5):1160-8. PubMed ID: 21233402 [TBL] [Abstract][Full Text] [Related]
20. Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs? Lee JY; Lim SH; Kim M; Kim S; Jung HA; Chang WJ; Choi MK; Hong JY; Lee SJ; Sun JM; Ahn JS; Park K; Ahn MJ Cancer Chemother Pharmacol; 2014 May; 73(5):1063-70. PubMed ID: 24663503 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]